Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used for short term management of moderate to severe acute pain. Its analgesic efficacy is comparable to moderate morphine doses in post-operative pain, without respiratory depression, dependence risk or opioid sedation. Ketorolac is used in post-surgical settings, for acute musculoskeletal pain and as ophthalmic drops for ocular inflammation.

Drug Class and How Ketorolac Works in the Body

Ketorolac belongs to the pyrrolo-pyrrole subclass of NSAIDs. It inhibits cyclo-oxygenase (COX) enzymes including COX-1 and COX-2 which catalyse the conversion of arachidonic acid into prostaglandins, the mediators of pain, fever and inflammation. Blocking prostaglandin synthesis reduces pain signalling peripherally, decreases local vasodilation & oedema and lowers fever, though its primary clinical use is analgesic.

Unlike selective COX-2 inhibitors, ketorolac inhibits both COX-1 and COX-2. COX-1 inhibition causes many side effects like reduced gastric mucosal protection, impaired platelet aggregation and altered renal prostaglandin synthesis regulating glomerular perfusion.

Approved Medical Uses of Ketorolac

Ketorolac is used for:

• Short-term management of moderate to severe acute pain: Post-operative pain following orthopaedic, abdominal, gynaecological or dental surgery is the most common indication

• Acute musculoskeletal pain: Fractures, sprains and soft tissue injuries in emergency settings where parenteral analgesia is required

• Renal colic: Effective for ureteric stone pain by reducing prostaglandin-mediated smooth muscle spasm; frequently used alongside buscopan in acute colic presentations

• Ophthalmic use: Ketorolac eye drops (0.5%) reduce inflammation and pain after cataract surgery, laser refractive procedures and allergic conjunctivitis

Ketorolac is not appropriate for chronic pain, cancer pain or headache. Systemic use is strictly limited to five days due to its gastrointestinal and renal toxicity profile on prolonged exposure.

Available Forms: Tablet, Injection, Eye Drops

Ketorolac is available as 10mg tablets, as a 15mg/mL or 30mg/mL solution for intramuscular or intravenous injection and as 0.5% ophthalmic eye drops. Oral bioavailability is approximately 80 to 100% but onset is slower than the injectable form. Intramuscular injection achieves peak plasma concentrations within 45 to 60 minutes. Intravenous administration produces analgesia within 10 to 15 minutes and is preferred for initial postoperative pain management. Total combined duration must not exceed five days.

How Ketorolac Is Different from Other NSAIDs

Two characteristics distinguish ketorolac from other NSAIDs. First, its analgesic potency is substantially higher (parenteral ketorolac 30mg produces analgesia comparable to morphine 10mg) making it a good opioid alternative. Second, its duration is uniquely restricted to five days, reflecting its higher rate of serious GI complications compared to ibuprofen or diclofenac.

Ketorolac has no central nervous system effects like sedation, respiratory depression or opioid-type dependence. This makes it particularly valuable where cognitive clarity or ventilatory function must be preserved alongside adequate analgesia.

Common and Serious Side Effects

Gastrointestinal effects are the most clinically significant. Nausea, dyspepsia, abdominal pain and diarrhoea occur in some patients. More serious: peptic ulcer formation, GI haemorrhage and perforation risk increasing with dose, duration, prior GI disease and concurrent aspirin or corticosteroid use. Ketorolac carries one of the highest GI complication rates among NSAIDs, which drives its strict five day limit.

Renal effects like acute kidney injury, fluid retention and hypertension arise from reduced prostaglandin-mediated renal perfusion, with highest risk in patients with kidney disease, heart failure, dehydration or those on diuretics or ACE inhibitors. Cardiovascular events like myocardial infarction and stroke are an NSAID class effect. Platelet function impairment increases surgical bleeding risk; ketorolac should be discontinued before elective procedures.

Who Should Not Take Ketorolac?

Certain groups of people should avoid taking ketorolac:

• Active peptic ulcer disease or history of gastrointestinal bleeding

• Severe renal impairment 

• Active hepatic failure

• Hypersensitivity to ketorolac or aspirin-sensitive asthma (NSAID cross-reactivity)

• Third trimester of pregnancy as NSAIDs cause premature closure of the ductus arteriosus and inhibit uterine contractions

• Cerebrovascular bleeding, haemorrhagic diathesis or incomplete haemostasis

• Perioperative use in CABG 

• Children below 16 years of age.

Drug Interactions You Must Know

Key interactions are:

• ACE inhibitors and ARBs

• Anticoagulants like warfarin, heparin & dabigatran

• Aspirin  

• Diuretics

• Lithium 

• Methotrexate

• Other NSAIDs

• SSRIs and SNRIs.

Special Precautions: Kidney, Liver, Elderly

• Renal: Any degree of renal impairment warrants caution. Mild to moderate CKD (eGFR 30 to 60 mL/min) requires dose reduction, monitoring of urine output & creatinine and avoidance of concurrent nephrotoxic agents. Ketorolac should not be given to dehydrated patients without fluid resuscitation.

• Elderly: Patients above 65 should receive the lowest effective dose for the shortest duration. Renal reserve declines with age even when creatinine appears normal and GI ulceration risk increases substantially. Maximum oral dose in elderly patients is 10mg every four to six hours not exceeding 40mg daily. 

• Liver: Severe hepatic impairment is a contraindication; mild to moderate liver disease needs caution and enzyme monitoring.

Overdose Symptoms and What to Do

Ketorolac overdose produces nausea, vomiting, epigastric pain and lethargy. Severe overdose may cause GI haemorrhage, acute renal failure and metabolic acidosis. There is no specific antidote and management is supportive: gastric lavage within one hour of ingestion, activated charcoal for recent oral ingestion, IV fluids and monitoring of renal function and electrolytes. Emergency assessment is required for suspected significant overdose.

Conclusion

Ketorolac is a potent analgesic with a narrow clinical role: short-term severe acute pain where opioid-sparing analgesia is the objective. Its non-dependence profile is a meaningful advantage. Its risks like GI haemorrhage, renal impairment and cardiovascular events are the reason its use is restricted to five days. In India, where it is available without prescription at many pharmacies, the five-day limit, contraindications and drug interactions require patient education to prevent harm from unsupervised use.

FAQs

1. What is ketorolac used for?

   Ketorolac is used for short-term management of moderate to severe acute pain like post-operative pain, acute musculoskeletal pain, and renal colic. Also used as eye drops for ocular inflammation after cataract and refractive surgery. Not appropriate for chronic pain.

2. Is ketorolac a strong painkiller?

   Yes one of the most potent NSAIDs available. Parenteral ketorolac 30mg produces analgesia comparable to morphine 10mg, without opioid-associated sedation, respiratory depression or dependence risk.

3. How long does ketorolac take to relieve pain?

   • Intravenous: Analgesia within 10 to 15 minutes. 

   • Intramuscular: Peak effect within 45 to 60 minutes. 

   • Oral tablets: 30 to 60 minutes for meaningful analgesia.

4. Can ketorolac be taken on an empty stomach?

   Ketorolac can be taken on an empty stomach but food reduces gastric irritation risk without affecting bioavailability. Taking it with food or a full glass of water is advisable given its GI toxicity potential.

5. Is ketorolac safe for long-term use?

   No ketorolac is contraindicated beyond 5 days of systemic use. This limit reflects substantially higher rates of GI ulceration and bleeding with longer exposure. It is not appropriate for chronic pain under any circumstances.

6. What makes ketorolac different from regular painkillers?

   Ketorolac's analgesic potency is significantly higher than other NSAIDs. It provides opioid equivalent pain relief without central nervous system effects. Its strict five-day limit and relatively high GI complication rate distinguish it from ibuprofen and diclofenac.

7. Can ketorolac cause stomach bleeding?

   Yes GI haemorrhage is among the most serious adverse effects. Risk is increased by prior peptic ulcer disease, concurrent aspirin or corticosteroid use, heavy alcohol consumption, age above 65 and use beyond five days. Patients with any GI risk factors should receive a proton pump inhibitor and the prescriber should weigh whether ketorolac is appropriate.

8. Is ketorolac an opioid or a steroid?

   Ketorolac is an NSAID with no opioid receptor activity and no opioid-type dependence and contains no corticosteroid. Its mechanism (COX enzyme inhibition) is entirely distinct from both opioid and steroid pharmacology.

9. Who should avoid taking ketorolac?

   Those with active peptic ulcer or GI bleeding history, severe kidney or liver disease, aspirin sensitive asthma, third-trimester pregnancy, bleeding disorders or those on anticoagulants should avoid ketorolac. The elderly require dose reduction and monitoring. Children below 16 should not receive ketorolac.

10. Can ketorolac be used for toothache or dental pain?

    Ketorolac provides effective analgesia for moderate to severe post-dental surgical pain. It is not appropriate for chronic dental pain or as a substitute for definitive treatment. Do not take it for more than five days and self-medication without dental assessment should be avoided.

References

1. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39(1):86–109. https://doi.org/10.2165/00003495-199039010-00007

2. Forrest JB, Camu F, Fischer HB, et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth. 2002;88(2):227–33. https://doi.org/10.1093/bja/88.2.227

3. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA. 1996;275(5):376–82. https://doi.org/10.1001/jama.1996.03530290050037

4. Pradhan BB, Tatsumi RL, Gallina J, Kuhns CA, Wang JC, Dawson EG. Ketorolac and spinal fusion — does the evidence warrant withholding perioperative ketorolac?. Spine. 2008;33(19):2079–82. https://doi.org/10.1097/BRS.0b013e318182018b

5. Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg. 2002;94(1):55–9. https://doi.org/10.1097/00000539-200201000-00010